#Japan #Tokyo #Clinical Trials #Drug Development #Taiho Innovations

Taiho Innovations Expands to Enhance Drug Development Efforts

Taiho Pharmaceuticals Co., Ltd., located in Chiyoda, Tokyo, and Taiho Innovations Ltd. have announced an important restructuring initiative that aims to enhance their capabilities in clinical development. This new framework, which becomes effective from July 1, 2026, reflects their commitment to advancing drug discovery and fostering collaboration with academic institutions and venture companies.

Founded in 2019, Taiho Innovations has acted as the corporate venture capital arm of Taiho Pharmaceuticals, investing in innovative projects while providing hands-on support to emerging biotech firms. With the increasing complexity of drug discovery processes, Taiho Innovations recognizes the need to enhance its clinical development functionalities to better support essential proof-of-concept (PoC) studies. These studies are vital in determining the viability and success of new therapies in the competitive pharmaceutical landscape.

To meet this challenge, Taiho Innovations is taking significant steps to establish a new early clinical development function. This involves transferring certain clinical development resources from Taiho Pharmaceuticals to Taiho Innovations. The focus will be on supporting early-stage clinical trials for drug candidates originating from academia and startup companies. By leveraging the extensive knowledge, experience, and networks of its personnel, Taiho Innovations aims to create a high-quality support system for these collaborative trials.

In addition to investment and incubation functions, the newly developed early clinical development capabilities will position Taiho Innovations as a unique co-creation foundation in Japan's biopharmaceutical sector. Through these efforts, Taiho Innovations aspires to expedite the acquisition of clinical PoC, ultimately leading to the creation of both medical and commercial value for innovative drug therapies. This structural enhancement is more than a mere administrative change; it reflects a strategic initiative to maximize the value of drug candidates and accelerate their practical application in the market.

Furthermore, as part of this reorganization, Taiho Innovations has transitioned from a limited liability company to a joint-stock corporation. The company also announced that Takahito Okubo has been appointed as the new President and CEO as of July 2, 2026. Under his leadership, Taiho Innovations is expected to further catalyze open innovation and contribute to the development of groundbreaking therapeutic solutions.

Taiho Pharmaceuticals and Taiho Innovations are poised to continue their multifaceted approach to promoting open innovation, while being at the forefront of creating new and innovative medicinal products.

Overview of Taiho Innovations Ltd.

• - Company Name: Taiho Innovations Ltd.
• - CEO: Takahito Okubo
• - Location: 1-9-8, Nihonbashi Horiduri-cho, Chuo-ku, Tokyo, Japan (Ningyocho PREX 5F), Toranomon Office: 1-17-1, Toranomon, Minato-ku, Tokyo, Japan (Toranomon Hills Business Tower 15F CIC Tokyo), Tsukuba Office: 3 Okubo, Tsukuba, Ibaraki, Japan
• - Founded: May 30, 2019
• - Business Functions: Venture capital activities, incubation services, research and contract development of pharmaceuticals and diagnostics, along with related consulting services.
• - Capital: 100 million JPY
• - Website: Taiho Innovations